Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Hansa Biopharma AB ( (SE:HNSA) ) just unveiled an update.
Hansa Biopharma announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference, where CEO Renée Aguiar-Lucander will engage in a Fireside chat. This participation highlights Hansa’s ongoing efforts to engage with investors and stakeholders, potentially impacting its industry positioning by showcasing its innovative treatments and strategic direction.
The most recent analyst rating on (SE:HNSA) stock is a Hold with a SEK33.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
More about Hansa Biopharma AB
Hansa Biopharma AB is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative treatments for rare immunological conditions. The company utilizes its proprietary IgG-cleaving enzyme technology platform to address unmet medical needs in autoimmune diseases, gene therapy, and transplantation. Its portfolio includes imlifidase, an IgG antibody-cleaving enzyme therapy for kidney transplantation, and HNSA-5487, a next-generation IgG cleaving molecule.
Average Trading Volume: 407,471
Technical Sentiment Signal: Hold
Current Market Cap: SEK2.82B
For a thorough assessment of HNSA stock, go to TipRanks’ Stock Analysis page.